• 1
    Chopra N, Kirschenbaum A, Widman D. Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis. J Clin Rheumatol 2002; 8: 2658.
  • 2
    Lam A, Toma W, Schlesinger N. Mycobacterium marinum arthritis mimicking rheumatoid arthritis. J Rheumatol 2006; 33: 8179.
  • 3
    Van Ingen J, Boeree M, Janssen M, Ullmann E, de Lange W, de Haas P, et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol 2007; 3: 4149.
  • 4
    Maimon N, Brunton J, Chan A, Marras TK. Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. Thorax 2007; 62: 73940.
  • 5
    Marie I, Heliot P, Roussel F, Herve F, Muir JF, Levesque H. Fatal Mycobacterium peregrinum in refractory polymyositis treated with infliximab [letter]. Rheumatology (Oxford) 2005; 44: 12012.
  • 6
    Boulman N, Rozenbaum M, Slobodin G, Rosner I. Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis [letter]. Clin Exp Rheumatol 2006; 24: 723.
  • 7
    Mufti A, Toye B, Mckendry R, Angel JB. Mycobacterium abscessus infection after use of tumor necrosis factor α inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor α inhibitor use. Diagn Microbiol Infect Dis 2005; 53: 2338.
  • 8
    Yim K, Nazeer S, Kiska D, Rose FB, Brown D, Cynamon MH. Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept. Scand J Infect Dis 2004; 36: 1503.
  • 9
    Thomas JE, Taoka CR, Gibbs BT, Fraser SL. Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept. Hawaii Med J 2006; 65: 125.
  • 10
    Flynn J, Goldstein M, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, et al. Tumor necrosis factor α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2: 56172.
  • 11
    Roach DR, Bean AG, Demangel C. TNF regulates the chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168: 462070.
  • 12
    Adhikesavan LG, Harrington TM. Local and disseminated infections caused by Mycobacterium marinum: an unusual cause of subcutaneous nodules. J Clin Rheumatol 2008; 14: 15660.
  • 13
    Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367416.
  • 14
    Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis. Drugs Aging 2007; 24: 23954.
  • 15
    Aubry A, Chosidow O, Caumes E, Robert J, Cambau E. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 2002; 162: 174652.
  • 16
    Matsumoto T, Tanaka T, Kawase I. Infliximab for rheumatoid arthritis in a patient with tuberculosis [letter]. N Engl J Med 2006; 355: 7401.
  • 17
    Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M, et al. A study of the safety, immunology, virology and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18: 25764.